(12) Patent Application Publication (10) Pub. No.: US 2002/0193322 A1 Baiocchi Et Al

Total Page:16

File Type:pdf, Size:1020Kb

(12) Patent Application Publication (10) Pub. No.: US 2002/0193322 A1 Baiocchi Et Al US 2002O193322A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0193322 A1 Baiocchi et al. (43) Pub. Date: Dec. 19, 2002 (54) METHOD OF PREPARING Publication Classification PHYSIOLOGICALLY ACCEPTABLE AQUEOUS SOLUTIONS, AND SOLUTIONS (51) Int. Cl." ....................... A61K 31/704; A61K 31/66; THUS OBTAINED A61K 31/60; A61K 31/551; A61K 31/525; A61K 31/522; (76) Inventors: Leandro Baiocchi, Roma (IT); Mauro A61K 31/57 De Gregorio, Roma (IT) (52) U.S. Cl. .............................. 514/33; 514/171; 514/75; 514/263.31; 514/165; 514/217.05; Correspondence Address: 514/220; 514/282; 514/569; OBLON SPIVAK MCCLELLAND MAIER & 514/251 NEUSTADT PC FOURTH FLOOR (57) ABSTRACT 1755JEFFERSON DAVIS HIGHWAY A physiologically acceptable aqueous Solution, and water ARLINGTON, VA 2.2202 (US) Soluble compositions Suitable for obtaining it, comprising a first physiologically acceptable compound of an acidic (21) Appl. No.: 10/058,080 nature and a Second physiologically acceptable compound of a basic nature that are able to give rise to a precipitate in (22) Filed: Jan. 29, 2002 water, characterized in that it also contains a trisubstituted Salt of glycyrrhizic acid in a Sufficient quantity to form a (30) Foreign Application Priority Data clear Solution in water. Jan. 30, 2001 (IT) ............................ RM2OO1A 000048 A method for preparing the Said Solution. US 2002/0193322 A1 Dec. 19, 2002 METHOD OF PREPARING PHYSIOLOGICALLY therapeutically useful concentration, and cases of partial ACCEPTABLE AOUEOUS SOLUTIONS, AND incompatibility in which it is possible to obtain solutions but SOLUTIONS THUS OBTANED only in a very restricted range of concentration. 0001. This application is based on application No. 0009. The problem of incompatibility is not solved by RM2001. A 000048 filed in Italy, the content of which is Separate administration of the Solutions of the different incorporated hereinto by reference. pharmacologically active compounds to the patient, unless there is a considerable interval of Space and/or time between 0002 The present invention relates to a method of pre the applications. Otherwise, in fact, incompatibility between paring physiologically acceptable aqueous Solutions and the two pharmacologically active compounds and inactiva water-Soluble compositions Suitable for obtaining them, as tion occur at the Site of actual application (See, for example, well as the Solutions and the compositions thus obtained. the case of cephalosporins and of aminoglycosides (REFI 0.003 More particularly, the present invention relates to page A-249)). In each case separate application, besides physiologically acceptable aqueous Solutions and water being inconvenient, proves completely impossible in Some Soluble compositions Suitable for obtaining them, compris cases, for example when one of the compounds performs the ing a first physiologically acceptable compound of an acidic functions of a preservative. nature, a Second physiologically acceptable compound of a basic nature and a trisubstituted Salt of glycyrrhizic acid. STATE OF THE ART 0010. In some cases the problem has been solved by BACKGROUND OF THE INVENTION using specific pharmaceutical formulations. Thus, the 0004. In therapeutic and cosmetic practice, both human incompatibility between certain carboxylic acids and certain and Veterinary, use is often made of aqueous Solutions basic decongestants is eliminated by means of a mixture of containing a carboxylic acid or an organic base, possessing polysorbates and a polyoxamer (U.S. Pat. No. 5,459,157). low intrinsic solubility (solubility of the undissociated com Moreover, it should be pointed out that in this case, as in pound). Their Salification (generally with alkali metals or other Similar cases, the concentration of these additives is hydrophilic amines of low molecular weight for the acids, very high (12%) relative to that of the pharmacologically and with hydrogen halides or hydrophilic organic acids of active compounds (0.05-0.1%). low molecular weight, for the bases) is employed to provide 0011 Glycyrrhizic acid, the principal component of the them with adequate Solubility. extract of Glycyrrhiza Glabra, was isolated by Karrer and 0005 Sometimes it is useful to have acqueous solutions Chao and its tricarboxylic acid structure was established by containing at least one carboxylic acid and at least one Ruzicka in 1943 (Merck Index, XII ed., 4515). Two epimers organic base at the same time. Since Solutions with basic pH of glycyrrhizic acid are known, designated 18O, and 18f3, but are needed for the Solubilization of weak organic acids, and the Second is the commonest and it is this that is being solutions with acid pH are needed for the solubilization of referred to whenever the nature of the epimer is nots weak organic bases, Such compounds often display a high expressly indicated (Runti, Fondamenti di chimica farma degree of incompatibility in ordinary aqueous Solutions ceutica Fundamentals of pharmaceutical chemistry, Trieste because mutual precipitation occurs on mixing them (see A. 1969, Vol. III, page 265). T. Florence & D. Attwood “Physiochemical Principles of 0012 Various salts of glycyrrhizic acid, called glycyr Pharmacy”, II edition, Portland Oreg., 1988, p. 154). rhizinates, have been described in the literature. 0006 Examples of this behaviour that are well known in 0013 A typical, commercially available monosubstituted the literature are the Solutions of acetylsalicylic acid (lysine salt is the monoammonium salt “Glycamil T.M.' of the com salt) with chlorpromazine (hydrochloride) or promethazine pany Indena of Milan. Typical disubstituted salts are the (hydrochloride) (Repertorio Farmaceutico Italiano 1989 dipotassium salt, “Ritamectant K2TM” of the R.I.T.A. Cor (REFI) page A-578); Solutions of furosemide (sodium salt) poration, and the mixed Salts of potassium, calcium and with organic bases (REFI, page A-808); Solutions of magnesium called “glycyrrhizines” (U.S. Pat. No. 4,176, dimenorfan (phosphate) with penicillin (Sodium salt) or of 228). A typical trisubstituted Salt is the tripotassium Salt sodium salicylate (REFI page A-646). (Voss et al., Ber. 70, 122, 1937). 0007. It should be noted, moreover, that the phenomenon 0014. The monosubstituted and disubstituted salts are is rather more complex than might appear at first sight widely used in the food and pharmaceutical industry, prin because, depending on circumstances, there may be precipi cipally as Sweeteners. tation of the acid compound, or of the basic compound, or of a mixture of the two, or of adducts, known as hydrophobic 0015 Apart from some mild therapeutic activities that ion pairs. In this last case, which is very common, there may have been under investigation for several years (antiulcer be formation of precipitates, even when one of the two activity, anti-AIDS activity, treatment of hepatitis B), certain components, for example quaternary ammonium com functions of glycyrrhizic acid and its Salts as “adjuvants' in pharmaceutical formulations have also been described from pounds, has good intrinsic Solubility. time to time. 0008. The incompatibility is more or less pronounced depending on the pK, on the nature and on the intrinsic 0016. The action of "enhancers' of absorption through Solubility of the components that determine it. In fact, cases the Skin and the mucous membranes is well documented of absolute incompatibility are encountered in practice, in (U.S. Pat. Nos. 5,183,802; 5,238,917; JP 3099023). which it is practically impossible to obtain Solutions con 0017 Japanese patent JP 10025255 proposes the use of taining the two pharmacologically active compounds at any glycyrrhizic acid, its Salts or its esters, for the preparation of US 2002/0193322 A1 Dec. 19, 2002 Solid complexes with antiulcer, anti-inflammatory or anti nature and a Second physiologically acceptable compound of histaminic drugs for the purpose of improving their absorp a basic nature that are able to give rise to a precipitate in tion (rate of Solution). It is known, however, that the water, characterized in that it also includes a trisubstituted complexes that can be used for increasing the rate of Solution Salt of glycyrrhizic acid in Sufficient quantity to form a clear cannot be used for increasing equilibrium Solubility (A. J. Solution. Repta in “Technique of Solubilation of Drugs” (S. H. 0025 Moreover, in a further aspect, the present invention Yalkowsky ed. Marcel Dekker N.Y. 1981 page 135 ff.; pages relates to a composition comprising a first physiologically 149 and 151). acceptable compound of an acidic nature and a Second 0018. In two Japanese patent documents (Jpn. Kokai physiologically acceptable compound of a basic nature that 0283,318 and JP 3145432A) reference is made to clear are able to give rise to a precipitate in water, characterized Solutions containing Salts of glycyrrhizic acid, quaternary in that it also includes a trisubstituted Salt of glycyrrhizic ammonium compounds and respectively, Sodium condoitr acid in Sufficient quantity to form a clear Solution when the insulphate, borax and taurine in the first case, and lysozime Said composition is added to water. (hydrochloride) in the second. In the first case (C.A. 113, 0026. For the purposes of the present invention, the 65296x) the salt used is dipotassium glycyrrhizinate. glycyrrhizic acid can be either in the form of epimer 18C, or 0019 U.S. Pat. No. 4,481,187 discloses the use of gly of epimer 18B. The latter is preferred, however, because it is cyrrhizic
Recommended publications
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Genl:VE 1970 © World Health Organization 1970
    Nathan B. Eddy, Hans Friebel, Klaus-Jiirgen Hahn & Hans Halbach WORLD HEALTH ORGANIZATION ORGANISATION .MONDIALE DE LA SANT~ GENl:VE 1970 © World Health Organization 1970 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization. For rights of reproduction or translation of WHO publications in toto, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. Authors alone are responsible for views expressed in signed articles. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. © Organisation mondiale de la Sante 1970 Les publications de l'Organisation mondiale de la Sante beneficient de la protection prevue par les dispositions du Protocole n° 2 de la Convention universelle pour la Protection du Droit d'Auteur. Les institutions gouvernementales et les societes savantes ou professionnelles peuvent, toutefois, reproduire des donnees, des extraits ou des illustrations provenant de ces publications, sans en demander l'autorisation a l'Organisation mondiale de la Sante. Pour toute reproduction ou traduction integrate, une autorisation doit etre demandee a la Division des Services d'Edition et de Documentation, Organisation mondiale de la Sante, Geneve, Suisse.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20050181041A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0181041 A1 Goldman (43) Pub. Date: Aug. 18, 2005 (54) METHOD OF PREPARATION OF MIXED Related US. Application Data PHASE CO-CRYSTALS WITH ACTIVE AGENTS (60) Provisional application No. 60/528,232, ?led on Dec. 9, 2003. Provisional application No. 60/559,862, ?led (75) Inventor: David Goldman, Portland, CT (US) on Apr. 6, 2004. Correspondence Address: Publication Classi?cation LEYDIG VOIT & MAYER, LTD (51) Int. Cl.7 ....................... .. A61K 31/56; A61K 38/00; TWO PRUDENTIAL PLAZA, SUITE 4900 A61K 9/64 180 NORTH STETSON AVENUE (52) US. Cl. ............................ .. 424/456; 514/179; 514/2; CHICAGO, IL 60601-6780 (US) 514/221 (73) Assignee: MedCrystalForms, LLC, Hunt Valley, (57) ABSTRACT MD This invention pertains to a method of preparing mixed phase co-crystals of active agents With one or more materials (21) Appl. No.: 11/008,034 that alloWs the modi?cation of the active agent to a neW physical/crystal form With unique properties useful for the delivery of the active agent, as Well as compositions com (22) Filed: Dec. 9, 2004 prising the mixed phase co-crystals. Patent Application Publication Aug. 18, 2005 Sheet 1 0f 8 US 2005/0181041 A1 FIG. 1a 214.70°C z.m."m.n... 206.98°C n..0ao 142 OJ/g as:20m=3: -0.8 -1.0 40 90 1:10 2110 Temperture (°C) FIG. 1b 0.01 as:22“.Km: 217 095 24221.4 39Jmum/Q -0.8 35 155 255 255 Temperture (°C) Patent Application Publication Aug.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew Et Al
    US009314465B2 (12) United States Patent (10) Patent No.: US 9,314.465 B2 Brew et al. (45) Date of Patent: *Apr. 19, 2016 (54) DRUG COMBINATIONS AND USES IN 2008.0003280 A1 1/2008 Levine et al. ................. 424/456 TREATING A COUGHING CONDITION 2008/O176955 A1 7/2008 Hecket al. 2008, 0220078 A1 9, 2008 Morton et al. (71) Applicant: Infirst Healthcare Limited 2009, O136427 A1 5/2009 Croft et al. 2009, O220594 A1 9, 2009 Field (72) Inventors: John Brew, London (GB); Robin Mark 2012/O128738 A1 5, 2012 Brew et al. Bannister, London (GB) 2012fO252824 A1 10/2012 Brew et al. (73) Assignee: Infirst Healthcare Limited, London FOREIGN PATENT DOCUMENTS (GB) CN 1593451 3, 2005 CN 101024.014 A 8, 2007 (*) Notice: Subject to any disclaimer, the term of this CN 101112383 B 5, 2010 patent is extended or adjusted under 35 DE 4420708 A1 12, 1995 U.S.C. 154(b) by 0 days. EP 2050435 B1 4/2009 GB 2114001 A 8, 1983 This patent is Subject to a terminal dis GB 2284761 A 6, 1995 claimer. GB 2424.185 B 9, 2006 GB 2442828 A 4/2008 JP 62-249924 A 10, 1987 (21) Appl. No.: 14/287,014 JP H1O-316568 A 12/1998 JP 2001-518928 A 10, 2001 (22) Filed: May 24, 2014 JP 200219.3839. A T 2002 JP 2003-012514 A 1, 2003 (65) Prior Publication Data JP 20030552.58 A 2, 2003 JP 2003128549 A 5, 2003 US 2014/O256750 A1 Sep. 11, 2014 JP 2003-321357 A 11, 2003 JP 2005-516917 A 6, 2005 JP 2008O31146 A 2, 2008 Related U.S.
    [Show full text]
  • Pharmacy and Poisons Act 1979
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS ACT 1979 1979 : 26 TABLE OF CONTENTS PART I PRELIMINARY 1 Short title 2 Interpretation PART II THE PHARMACY COUNCIL 3 The Pharmacy Council 4 Membership of the Council 4A Functions of the Council 4B Protection from personal liability 4C Annual Report 5 Proceedings of the Council, etc PART III REGISTRATION OF PHARMACISTS 6 Offence to practise pharmacy if not registered 7 Registration as a pharmacist 7A Re-registration as non-practising member 7AA Period of validity of registration 8 Code of Conduct 9 Pharmacy Profession Complaints Committee 10 Investigation of complaint by Committee 10A Inquiry into complaint by Council 10B Inquiry by Council of its own initiative 11 Surrender of registration 12 Restoration of name to register 1 PHARMACY AND POISONS ACT 1979 13 Proof of registration 14 Appeals 14A Fees 14B Amendment of Seventh Schedule 15 Regulations for this part PART IV REGISTRATION OF PHARMACIES 16 Register of pharmacies 17 Registration of premises as registered pharmacies 18 Unfit premises: new applications 19 Unfit premises: registered pharmacies 20 Appeals 21 When certificates of unfitness take effect 22 Regulations for this Part PART V CONTROL OF PRESCRIPTIONS AND IMPORTATION 23 Prescriptions to be in a certain form 23A Validity of a prescription 24 Supply by registered pharmacist of equivalent medicines 25 Restrictions on the importation of medicines 26 Declaration relating to imported medicines [repealed] PART VI CONTROL OF DRUGS 27 Certain substances to be sold on prescription
    [Show full text]
  • Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors
    저작자표시-비영리-변경금지 2.0 대한민국 이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게 l 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다. 다음과 같은 조건을 따라야 합니다: 저작자표시. 귀하는 원저작자를 표시하여야 합니다. 비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다. 변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다. l 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건 을 명확하게 나타내어야 합니다. l 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다. 저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다. 이것은 이용허락규약(Legal Code)을 이해하기 쉽게 요약한 것입니다. Disclaimer 약학 석사학위 논문 안지오텐신 전환 효소 억제제 개시 이후 진해제의 사용 분석 Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors 2017년 8월 서울대학교 대학원 약학과 사회약학전공 권 익 태 안지오텐신 전환 효소 억제제 개시 이후 진해제의 사용 분석 Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors 지도교수 홍 송 희 이 논문을 권익태 석사학위논문으로 제출함 2017년 4월 서울대학교 대학원 약학과 사회약학전공 권 익 태 권익태의 석사학위논문을 인준함 2017년 6월 위 원 장 (인) 부 위 원 장 (인) 위 원 (인) Abstract Use of Antitussives After the Initiation of Angiotensin-Converting Enzyme Inhibitors Ik Tae Kwon Department of Social Pharmacy College of Pharmacy, Seoul National University Background Angiotensin-converting enzyme inhibitors (ACEI) can induce a dry cough, more frequently among Asians. If healthcare professionals fail to detect coughs induced by an ACEI, patients are at risk of getting antitussives inappropriately instead of discontinuing ACEI. The purpose of this study was to examine how the initiation of ACEI affects the likelihood of antitussive uses compared with the initiation of Angiotensin Receptor Blocker (ARB) and to determine the effect of the antitussive use on the duration and adherence of therapy in a Korean population.
    [Show full text]
  • Elif Fatma Sen BW.Indd
    Use and Safety of Respiratory Medicines in Children E. F. Şen EEliflif FFatmaatma SSenen BBW.inddW.indd 1 003-01-113-01-11 115:175:17 The work presented in this thesis was conducted at the Department of Medical Informatics of the Erasmus University Medical Center, Rotterdam. The research reported in thesis was funded by the European Community’s 6th Framework Programme. Project number LSHB-CT-2005-005216: TEDDY: Task force in Europe for Drug Development for the Young. The contributions of the participating primary care physicians in the IPCI, Pedianet and IMS-DA project are greatly acknowledged. Financial support for printing this thesis was kindly provided by the department of Medical Informatics – Integrated Primary Care Information (IPCI) project of the Erasmus University Medi- cal Center; and by the J.E. Jurriaanse Stichting in Rotterdam. Cover: Optima Grafi sche Communicatie Printed by: Optima Grafi sche Communicatie Elif Fatma Şen Use and Safety of Respiratory medicines in Children ISBN: 978-94-6169-003-6 © E.F. Şen, Rotterdam, the Netherlands, 2011. All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without prior written permission of the holder of the copyright. EEliflif FFatmaatma SSenen BBW.inddW.indd 2 003-01-113-01-11 115:175:17 Use and Safety of Respiratory Medicines in Children Het gebruik en de bijwerkingen van respiratoire medicijnen in kinderen Proefschrift Ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnifi cus Prof.dr.
    [Show full text]
  • User's Manual for the SABE Databases
    User's Manual for the SABE Databases Pan American Health Organization ,.. , ) '· ~~'-~ l!c, , ~0//,rr olthe •! · 0 World Hea lth Organization ' Washington, D.C. September 2004 The user's manual for the SABE survey databases was prepared by the SABE regional coordination team of the Pan American Health Organization, Washington, DC, August 2004. International teams responsible for the survey in each of the seven cities provided technical support for the preparation and review of this document. Comments, questions, or requests for information can be directed to Martha Pelaez at [email protected] 2 TABLE OF CONTENTS INTRODUCTION .................................... ........................... ..... ............... ... .......... ... 4 PRINCIPAL SABE SURVEY RESEARCHERS ... ............ .... ................................................. 6 DESIGN OF THE SAMPLE ...................... .............................. .. .......... ............... .. 7 DIRECT, PROXY, AND ASSISTED INTERVIEWS ......... .......................... .. ..... .. .. ............. ... 15 SECTION A: GENERAL DATA .................................... ... .. ................... ...... ............ ... 16. Identification of the Gender of the Interviewee A3 Classification and Code: Birthplace A11a Religion A12 Ethnic Group A 13 History of Relationships and Marital Status SECTION 8: COGNITIVE STATUS ......... .. .. ............. .. ..... .. .. .. ·-· ......................... ...... ... .20 Mini Mental State Examination (MMSE) Pfeffer SECTION C: HEALTH STATUS .... ...................
    [Show full text]
  • Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services
    Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services Australian Statistics on Medicines 1997 i © Commonwealth of Australia 1998 ISBN 0 642 36772 8 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be repoduced by any process without written permission from AusInfo. Requests and enquiries concerning reproduction and rights should be directed to the Manager, Legislative Services, AusInfo, GPO Box 1920, Canberra, ACT 2601. Publication approval number 2446 ii FOREWORD The Australian Statistics on Medicines (ASM) is an annual publication produced by the Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee. Comprehensive drug utilisation data are required for a number of purposes including pharmacosurveillance and the targeting and evaluation of quality use of medicines initiatives. It is also needed by regulatory and financing authorities and by the Pharmaceutical Industry. A major aim of the ASM has been to put comprehensive and valid statistics on the Australian use of medicines in the public domain to allow access by all interested parties. Publication of the Australian data facilitates international comparisons of drug utilisation profiles, and encourages international collaboration on drug utilisation research particularly in relation to enhancing the quality use of medicines and health outcomes. The data available in the ASM represent estimates of the aggregate community use (non public hospital) of prescription medicines in Australia. In 1997 the estimated number of prescriptions dispensed through community pharmacies was 179 million prescriptions, a level of increase over 1996 of only 0.4% which was less than the increase in population (1.2%).
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Australian Statistics on Medicines 1999–2000
    Commonwealth Department of Health and Ageing Australian Statistics on Medicines 1999–2000 © Commonwealth of Australia 2003 ISBN 0 642 82184 4 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from the Commonwealth available from AusInfo. Requests and inquiries concerning reproduction and rights should be addressed to the Manager, Legislative Services, AusInfo, GPO Box 1920, Canberra ACT 2601. Publications Approval Number: 3183 (PA7270) FOREWORD Comprehensive and valid statistics on use of medicines by Australians in the public domain should be accessible to all interested parties. From the first edition in 1992 until 1999 the Drug Utilisation SubCommittee (DUSC) produced the Australian Statistics on Medicines (ASM) for each calendar year to 1998. It is pleasing indeed to be able to present these again this year, with the inclusion of estimates for the years since the last edition. A continuous data set representing estimates of the aggregate community use (non public hospital) of prescription medicines in Australia is a key tool for the Australian Medicines Policy. The ASM presents dispensing data on most drugs marketed in Australia and is the only current source of data in Australia to cover all prescription medicines dispensed in the community. Drug utilisation data can assist the targeting and evaluation of quality use of medicines initiatives, and the evaluation of changes to the availability of medicines. It is also needed for pharmacosurveillance by regulatory and financing authorities and by the Pharmaceutical Industry. Publication of the Australian data also facilitates international comparisons of drug utilisation profiles and encourages international collaboration on drug utilisation research particularly in relation to enhancing the quality use of medicines and health outcomes.
    [Show full text]
  • Composition for Use in Treating and Preventing Inflammation Related Disorder
    (19) TZZ 54¥¥7A_T (11) EP 2 543 357 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 09.01.2013 Bulletin 2013/02 A61K 9/00 (2006.01) A61K 47/36 (2006.01) (21) Application number: 11173000.8 (22) Date of filing: 07.07.2011 (84) Designated Contracting States: (72) Inventor: Lin, Shyh-Shyan AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Taipei (TW) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Becker Kurig Straus Designated Extension States: Bavariastrasse 7 BA ME 80336 München (DE) (71) Applicant: Holy Stone Healthcare Co.,Ltd. Taipei City (TW) (54) Composition for use in treating and preventing inflammation related disorder (57) The presentinvention isrelated to ause fortreat- ease, coeliac disease, conjunctivitis, otitis, allergic rhin- ing and preventing inflammation related disorder of a itis, gingivitis, aphthous ulcer, bronchitis, gastroesopha- composition containing a drug and hyaluronic acid (HA) geal reflux disease (GERD), esophagitis, gastritis, en- or HA mixture, whereas the HA or the HA mixture as a teritis, peptic ulcer, inflammatory bowel disease (IBD), delivery vehicle can be a formulation including at least Crohn’s Disease, irritable bowel syndrome (IBS), intes- two HAs having different average molecular weights. The tinal inflammation or allergy, urethritis, cystitis, vaginitis, composition has been demonstrated to be capable of proctitis, eosinophilic gastroenteritis, or rheumatoid ar- reducing the therapeutic dose of a drug on the treatment thritis. and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary dis- EP 2 543 357 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 2 543 357 A1 2 Description alleviate pain by counteracting the cyclooxygenase (COX) enzyme.
    [Show full text]